Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 27 Sep 2026 · Editorial standards

At a glance

argenx is the lead sponsor of 44 current clinical trials in our USA, Spain, Italy, Poland, Germany, UK, France, Canada, Belgium, Austria, Japan, Netherlands, Czechia, China, Portugal, Australia, Denmark, Israel, South Korea, Sweden, Brazil, Ireland, Norway, Turkey, Mexico, Switzerland, Taiwan, Singapore and EU (CTIS) registers. 23 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Empasiprubart, Efgartigimod PH20 and Efgartigimod. The most-studied condition is gMG.

Company profile on this site (news, sites, medicines, approvals): Argenx (BE) →

ClinicalTrials.gov trials by status

Recruiting2359%
Not yet open25%
Active, closed1231%
By invitation25%

Trials by phase

Phase 31128%
Phase 21128%
Observational718%
Phase 1513%
Phase 2/3410%
Phase 413%

Clinical trials sponsored by argenx

39 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis NCT06392386 · Generalized Myasthenia Gravis Drug: Efgartigimod PH20	Phase 2/3	Recruiting	2024-06	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Czechia, Canada, Australia, Israel
A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4 NCT06078553 · Congenital Myasthenic Syndrome	Observational	Recruiting	2024-02	UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Austria, Canada, Brazil, Japan
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis NCT07673627 · AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (MG), MG - Myasthenia Gravis Drug: Empasiprubart	Phase 2	Recruiting	2026-07	USA
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia NCT06544499 · ClinicalTrials.gov ↗ · Primary Immune Thrombocytopenia (ITP) Drug: Efgartigimod	Phase 3	Recruiting	2024-10	Ireland, UK, USA, China, Germany, France, Spain, Italy, Poland, Austria, Czechia, Portugal
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP NCT06920004 · ClinicalTrials.gov ↗ · Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy Drugs: Empasiprubart, IVIG	Phase 3	Recruiting	2025-08	UK, USA, Germany, France, Spain, Italy, Netherlands, Sweden, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Singapore, Australia, Israel
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP NCT07091630 · ClinicalTrials.gov ↗ · Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy Drug: Empasiprubart	Phase 3	Recruiting	2025-09	UK, USA, China, France, Italy, Netherlands, Denmark, Poland, Austria, Czechia, Brazil, Japan, South Korea, Singapore, Israel
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP) NCT07194850 · ClinicalTrials.gov ↗ · Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP Drug: Efgartigimod	Phase 2/3	Recruiting	2025-10	UK, Germany, France, Spain, Italy, Poland, Japan
Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study NCT07264426 · Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) Drug: Efgartigimod PH20	Observational	Recruiting	2025-08	USA, Germany
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding. NCT06299748 · Myasthenia Gravis, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy Drug: Efgartigimod	Observational	Recruiting	2023-11	USA, Germany, Spain, Italy
A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasthenia Gravis (gMG) in Italy NCT07595653 · ClinicalTrials.gov ↗ · Generalized Myasthenia Gravis (gMG), gMG	Observational	Recruiting	2026-02	Italy
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis NCT06655155 · ClinicalTrials.gov ↗ · Systemic Sclerosis (SSc)	Phase 2	Recruiting	2024-11	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Czechia, Portugal, Mexico
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis NCT04833894 · ClinicalTrials.gov ↗ · Generalized Myasthenia Gravis Drug: Efgartigimod	Phase 2/3	Recruiting	2021-10	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Canada
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy NCT07287982 · ClinicalTrials.gov ↗ · Spinal Muscular Atrophy (SMA) Drug: ARGX-119	Phase 2	Recruiting	2025-12	UK, USA
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease. NCT07596849 · ClinicalTrials.gov ↗ · Graves Disease Drug: Efgartigimod PH20	Phase 3	Recruiting	2026-06	Spain, Poland, Canada, Japan
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa NCT06298565 · ClinicalTrials.gov ↗ · Myasthenia Gravis Drug: Efgartigimod	Observational	Recruiting	2024-11	USA, Germany, Spain, Italy, Belgium, Austria, Israel
A Study to Assess the Bioequivalence of Efgartigimod PH20 SC Between Autoinjector and Prefilled Syringe in Healthy Adult Participants NCT07782775 · ClinicalTrials.gov ↗ · Healthy Volunteer, Healthy Adult Participants	Phase 1	Recruiting	2026-06	Canada
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis NCT07294170 · ClinicalTrials.gov ↗ · Myasthenia Gravis, MG, gMG Drugs: Efgartigimod, Empasiprubart	Observational	Recruiting	2025-12	USA, Germany, Spain, Italy, Belgium, Poland, Japan
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod NCT07284420 · ClinicalTrials.gov ↗ · AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG Drugs: Efgartigimod, Empasiprubart	Phase 2	Recruiting	2025-12	USA, Germany, Spain, Italy, Belgium, Poland, Japan
A Study to Assess the Safety of ARGX-124 in Healthy Volunteers NCT07377396 · ClinicalTrials.gov ↗ · Healthy Volunteers	Phase 1	Recruiting	2026-01	Canada
A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus Intravenous (IV) in Healthy Adult Participants NCT07612020 · ClinicalTrials.gov ↗ · Healthy Volunteers Drug: Empasiprubart	Phase 1	Recruiting	2026-03	Canada
A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG) NCT06909214 · ClinicalTrials.gov ↗ · New Onset Generalized Myasthenia Gravis (gMG) Drug: Efgartigimod PH20	Phase 4	Recruiting	2025-04	USA
A Study to Assess the Absolute Bioavailability and How Adimanebart SC Moves Through the Body in Healthy Adult Participants NCT07673601 · ClinicalTrials.gov ↗ · Healthy Volunteers (HV), Healthy Volunteer	Phase 1	Recruiting	2026-06	Canada
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease NCT07570316 · ClinicalTrials.gov ↗ · Graves' Disease, Graves Disease Drug: Efgartigimod PH20	Phase 3	Recruiting	2026-06	USA
A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults NCT07583641 · Autoimmune Encephalitis (AE)	Phase 2	Not yet open	2027-04	USA
A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN NCT07773727 · ClinicalTrials.gov ↗ · Immunoglobulin A Nephropathy (IgAN)	Phase 2	Not yet open	2026-10	USA
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy NCT05979441 · Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis Drug: Efgartigimod PH20	Phase 3	By invitation	2023-09	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Portugal, Mexico, Japan, South Korea, Taiwan
Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis NCT05374590 · Generalized Myasthenia Gravis, gMG Drugs: Efgartigimod, Efgartigimod PH20	Phase 2/3	By invitation	2022-08	UK, USA, Germany, France, Spain, Netherlands, Belgium, Poland, Canada, Israel
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia NCT04812925 · Primary Immune Thrombocytopenia Drug: Efgartigimod PH20	Phase 3	Active, closed	2021-11	Ireland, UK, USA, China, Italy, Poland, Norway, Portugal, Turkey, Mexico, Japan, South Korea, Australia
A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy NCT05405361 · Multifocal Motor Neuropathy (MMN) Drug: Empasiprubart	Phase 2	Active, closed	2023-01	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Canada
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis NCT06298552 · Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized Drug: Efgartigimod	Phase 3	Active, closed	2024-04	UK, USA, China, Germany, France, Spain, Netherlands, Belgium, Denmark, Poland, Czechia, Norway, Portugal, Canada
ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function NCT05907096 · ClinicalTrials.gov ↗ · Delayed Graft Function Drug: Empasiprubart	Phase 2	Active, closed	2024-02	USA, France, Spain, Italy, Belgium, Sweden, Austria, Portugal, Canada, Brazil, Australia
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis NCT06558279 · ClinicalTrials.gov ↗ · Myasthenia Gravis, Ocular	Phase 3	Active, closed	2024-09	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Portugal, Canada, Japan, South Korea, Australia
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome NCT06684847 · ClinicalTrials.gov ↗ · Primary Sjogrens Disease Drug: Efgartigimod PH20	Phase 3	Active, closed	2025-01	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Austria, Portugal, Turkey, Canada, Mexico, Japan, South Korea, Australia, Israel
A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy NCT06742190 · ClinicalTrials.gov ↗ · Multifocal Motor Neuropathy (MMN), MMN Drugs: Empasiprubart, Immunoglobulin, IVIG	Phase 3	Active, closed	2024-12	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Canada, Brazil, Japan, Australia
A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS) NCT06436742 · ClinicalTrials.gov ↗ · Congenital Myasthenic Syndrome, CMS Drug: ARGX-119	Phase 1	Active, closed	2024-09	UK, USA, France, Spain, Italy, Canada
A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy NCT05988073 · ClinicalTrials.gov ↗ · Multifocal Motor Neuropathy	Observational	Active, closed	2023-11	UK, USA, China, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Canada, Japan, Australia
A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR) NCT06503731 · ClinicalTrials.gov ↗ · Antibody-mediated Rejection	Phase 2	Active, closed	2024-08	USA, Germany, France, Spain, Belgium, Austria, Czechia, Canada
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis NCT06284954 · ClinicalTrials.gov ↗ · Dermatomyositis, Myositis Drug: Empasiprubart	Phase 2	Active, closed	2024-08	USA, Spain, Italy, Poland
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) NCT04280718 · ClinicalTrials.gov ↗ · Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug: Efgartigimod PH20	Phase 2	Active, closed	2020-09	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Austria, Czechia, Turkey, Japan, Taiwan, Israel

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

argenx in the EU trials register (CTIS)

5 trials

Authorised or ongoing trials in the EU Clinical Trials Information System with argenx as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

Study	Phase	Status	Countries
A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Participants with Sjogren’s Disease-Associated Sensorimotor or Sensory Polyneuropathy 2026-526218-10-00 · Immune System Diseases	Phase 2	Authorised	Germany, Estonia, Lithuania + 10 more
Master Protocol Full Title- A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis. ISA 2 to Master Protocol ARGX-999-2-MG-2000 – an Exploratory, Phase 2a, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis 2025-522939-33-00 · Immune System Diseases Drug: Empasiprubart	Phase 2	Ongoing	Greece, Italy, Germany + 4 more
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Empasiprubart IV in Adults With Chronic Inflammatory Demyelinating Polyneuropathy 2025-520805-10-00 · CTIS ↗ · Nervous System Diseases Drug: Empasiprubart	Phase 3	Ongoing	Czechia, Denmark, Poland + 12 more
A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy 2024-520097-36-00 · CTIS ↗ · Nervous System Diseases Drug: Empasiprubart	Phase 3	Ongoing	Czechia, Bulgaria, Netherlands + 16 more
ARGX-113-2409: A Multicenter, Randomized, Double-blinded, Parallel-Arm, Placebo- Controlled, Pharmacokinetic and Pharmacodynamic Study Followed by an Open-Label Arm to Evaluate Efgartigimod IV in Pediatric Participants from 12 Years to Less Than 18 Years of Age with Chronic ITP 2025-521055-23-00 · CTIS ↗ · Immune System Diseases	Phase 3	Ongoing	Lithuania, Romania, Hungary + 5 more

Drugs in argenx trials

6 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Empasiprubart13 Efgartigimod PH2010 Efgartigimod9 ARGX-1192 IVIG2 Immunoglobulin1

Conditions in argenx trials

45 conditions

gMG6Generalized Myasthenia Gravis5 Myasthenia Gravis5CIDP3Myositis2Dermatomyositis2Congenital Myasthenic Syndrome2Multifocal Motor Neuropathy (MMN)2Chronic Inflammatory Demyelinating Polyneuropathy2CIDP - Chronic Inflammatory Demyelinating Polyneuropathy2Chronic Inflammatory Demyelinating Polyradiculoneuropathy2AChR-Ab Seropositive Generalized Myasthenia Gravis2MG2Graves Disease2 Healthy Volunteer2 Healthy Volunteers2Primary Immune Thrombocytopenia1Active Idiopathic Inflammatory Myopathy1Polymyositis1Primary Immune Thrombocytopenia (ITP)1Primary Sjogrens Disease1Myasthenia Gravis, Generalized1CMS1Immune Thrombocytopenia (ITP)1

By trial register

Register	Trials	Recruiting
Clinical trials in USA	32	16
Clinical trials in Spain	25	12
Clinical trials in Italy	24	13
Clinical trials in Poland	22	11
Clinical trials in Germany	22	12
Clinical trials in UK	20	9
Clinical trials in France	20	8
Clinical trials in Canada	19	9
Clinical trials in Belgium	18	7
Clinical trials in Austria	15	6
Clinical trials in Japan	14	7
Clinical trials in Netherlands	13	5
Clinical trials in Czechia	12	5
Clinical trials in China	10	2
Clinical trials in Portugal	10	3
Clinical trials in Australia	8	2
Clinical trials in Denmark	8	2
Clinical trials in Israel	7	4
Clinical trials in South Korea	6	2
Clinical trials in Sweden	6	1
Clinical trials in Brazil	5	3
Clinical trials in Ireland	4	1
Clinical trials in Norway	4	1
Clinical trials in Turkey	4	1
Clinical trials in Mexico	4	1
Clinical trials in Switzerland	4	3
Clinical trials in Taiwan	2	0
Clinical trials in Singapore	2	2
EU register (CTIS)	5	—

A trial with sites in more than one country appears in each of those registers.

Questions about argenx trials

How many clinical trials does argenx sponsor?

argenx is the lead sponsor of 39 current trials on ClinicalTrials.gov in our USA, Spain, Italy, Poland, Germany, UK, France, Canada, Belgium, Austria, Japan, Netherlands, Czechia, China, Portugal, Australia, Denmark, Israel, South Korea, Sweden, Brazil, Ireland, Norway, Turkey, Mexico, Switzerland, Taiwan and Singapore registers, and 5 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.

Are argenx trials recruiting?

Yes. 23 of its 39 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is argenx testing?

Its current trials name 6 drugs and biologicals as interventions. The most frequent are Empasiprubart (13), Efgartigimod PH20 (10), Efgartigimod (9), ARGX-119 (2) and IVIG (2). The number in brackets is how many of its trials name each drug.

Does argenx have clinical trials in Ireland?

Yes. 4 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

argenx clinical trials